Viatris appoints Dr. Rogério Vivaldi Coelho to Board of Directors

Viatris Inc

Appointment effective June 3, 2024; expands Board from 11 to 12 members.
Dr. Vivaldi joins the reestablished Science and Technology Committee.
Former CEO of Sigilon Therapeutics (acquired by Eli Lilly, 2023) and executive at Bioverativ, Spark Therapeutics, and Genzyme.
Led successful approval of more than 15 orphan products across 20+ countries during Genzyme tenure.
Will receive standard compensation for non-employee directors; indemnification agreement executed.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Rogério Vivaldi Coelho

Director

VTRS · Viatris Inc

Effective: 2024-06-03
Filed: June 3, 2024, 7:59 PM ET

On June 3, 2024, the Board of Directors (the “Board”) of Viatris Inc. (the “Company”) increased the number of directors on the Board from 11 to 12 and appointed Rogério Vivaldi Coelho, M.D., M.B.A. as an independent (as defined in the applicable NASDAQ listing rules) member of the Board with a term of office expiring at the Company’s 2024 annual meeting of shareholders and appointed him to the recently reestablished Science and Technology Committee of the Board, each appointment effective June 3, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Rogério Vivaldi Coelho was appointed as Director at Viatris Inc.

Action: appointed
Role: Director

Exact text from the filing

On June 3, 2024, the Board of Directors (the “Board”) of Viatris Inc. (the “Company”) increased the number of directors on the Board from 11 to 12 and appointed Rogério Vivaldi Coelho, M.D., M.B.A. as an independent (as defined in the applicable NASDAQ listing rules) member of the Board with a term of office expiring at the Company’s 2024 annual meeting of shareholders and appointed him to the recently reestablished Science and Technology Committee of the Board, each appointment effective June 3, 2024.

View on SEC.gov

Viatris Inc filing history →

Source: SEC EDGAR

accession 0001193125-24-152351

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.